CASI Pharmaceuticals (CASIF) Accounts Payables (2021 - 2025)

CASI Pharmaceuticals has reported Accounts Payables for 5 years, with the latest figure at $24.2 million in Q4 2025.

• For the quarter ending Q4 2025, Accounts Payables rose 787.66% year-over-year to $24.2 million; the trailing twelve-month figure through Dec 2025 stood at $24.2 million (up 787.66% YoY), and the FY2025 full-year result was $24.2 million, up 787.66% from the prior year.
• Accounts Payables for Q4 2025 stood at $24.2 million, up from $2.7 million in the prior quarter.
• The five-year high for Accounts Payables was $24.2 million in Q4 2025, with the low at $2.2 million in Q4 2021.
• Historically, Accounts Payables has averaged $7.4 million across 5 years, with a median of $3.3 million in 2022.
• Annual changes were most pronounced in 2024 — Accounts Payables tumbled 38.64% — and 2025, when it jumped 787.66%.
• CASI Pharmaceuticals' Accounts Payables stood at $2.2 million in 2021, then soared by 47.95% to $3.3 million in 2022, then jumped by 34.93% to $4.4 million in 2023, then sank by 38.64% to $2.7 million in 2024, then jumped by 787.66% to $24.2 million in 2025.
• The last three Accounts Payables figures came in at $24.2 million (Q4 2025), $2.7 million (Q4 2024), and $4.4 million (Q4 2023), per Business Quant data.